Mar 13, 2018 4:25 pm EDT SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update
Mar 6, 2018 9:25 am EST SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants
Feb 1, 2018 8:30 am EST SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
